Average Co-Inventor Count = 5.22
ph-index = 8
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Abbvie Stemcentrx LLC (19 from 40 patents)
2. Stemcentrx, Inc. (14 from 18 patents)
3. Agensys, Inc. (9 from 196 patents)
4. Seattle Genetics, Inc. (5 from 132 patents)
5. Tae Life Sciences, LLC (5 from 7 patents)
6. Seagen Inc. (3 from 64 patents)
7. Medimmune Limited (2 from 541 patents)
8. Amgen Fremont Inc. (1 from 78 patents)
9. Celldex Therapeutics Limited (1 from 45 patents)
10. Curagen Corporation (84 patents)
11. Abgenix, Inc. (32 patents)
49 patents:
1. 12319707 - Dosage unit form(s) comprising BTS and BTS(OMe) for use in boron neutron capture therapy and methods thereof
2. 12139503 - Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof
3. 11884688 - Borylated amino acid compositions comprising BTS and BTS(OMe) for use in boron neutron capture therapy and methods thereof
4. 11566031 - Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof
5. 11559582 - Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
6. 11219689 - Boron enriched linker ('BEL') compositions for boron neutron capture therapy and methods thereof
7. 11033634 - Light chain variable regions
8. 10894090 - Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
9. RE48389 - Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
10. 10533051 - Anti SEZ6 antibodies and methods of use
11. 10478509 - Anti-DLL3 antibody drug conjugates for treating cancer
12. 10137204 - Anti-DLL3 antibody drug conjugates for treating cancer
13. 9968687 - Anti-DLL3 antibody drug conjugates
14. 9962454 - Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
15. 9937268 - Anti-DLL3 antibody drug conjugates and methods of use